Evaluation of 0.6% sodium alginate as a submucosal injection material in endoscopic submucosal dissection for early gastric cancer. Issue 5 (24th March 2014)

• Record Type: Journal Article
• Authors: Kusano, Toru; Etoh, Tsuyoshi; Akagi, Tomonori; Ueda, Yoshitake; Shiroshita, Hidefumi; Yasuda, Kazuhiro; Satoh, Masahiro; Inomata, Masafumi; Shiraishi, Norio; Kitano, Seigo
• Is Part Of: Digestive endoscopy. Volume 26:Issue 5(2014:Sep.)
• Page Start: 638
• Page End: 645
• Publication Date: 2014-03-24
• Subjects: Digestive organs -- Diseases -- Periodicals; Digestive organs -- Diseases -- Diagnosis -- Periodicals; Endoscopy -- Periodicals; Digestive System Diseases -- diagnosis -- Periodicals; Digestive System Diseases -- therapy -- Periodicals; Endoscopy -- Periodicals; 616.3
• DOI: 10.1111/den.12268
• Languages: English
• ISSNs: 0915-5635

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="den12268-sec-0001" sec-type="section"> <title>Background and Aim</title> <p>We have focused on sodium alginate (SA) solution as a potential submucosal injection material for endoscopic submucosal dissection (ESD). A previous SA solution had high viscosity and problems such as difficult handling. After its properties were adjusted, SA solution was examined <italic>in vitro</italic> and its clinical safety was evaluated.</p> </sec> <sec id="den12268-sec-0002" sec-type="section"> <title>Methods</title> <p>With 0.4% sodium hyaluronate (SH) solution as a control, catheter injectability and mucosa‐elevating capacity of 0.3–0.8% SA solutions were evaluated. Next, 0.6% SA solution was used for ESD in 10 patients with early gastric cancer in a prospective clinical study.</p> </sec> <sec id="den12268-sec-0003" sec-type="section"> <title>Results</title> <p>Compared with 0.4% SH solution, 0.6% SA solution exhibited no significant difference in catheter injectability but significant superiority in mucosa‐elevating capacity. In the clinical study, no adverse events were observed in any patient.</p> </sec> <sec id="den12268-sec-0004" sec-type="section"> <title>Conclusion</title> <p>The safety of 0.6% SA solution as a submucosal injection material was confirmed and it is suggested that its efficacy should be investigated in a larger number of cases.</p> </sec> </abstract>